ADM Diagnostics (ADMdx)

04/22/2026

Encouraging to see the recent data on Leqembi's (anti-amyloid therapy) ability to slow the rate of clinical decline in Alzheimer's Disease for a sustained, 48 month period, as presented at the AAN Annual Meeting:

An IV drip

04/22/2026

Our newly published paper describes the relationship between plasma p-tau 217, a biomarker in blood that reflects amyloid and tau, and FDG PET imaging, which measures brain glucose metabolism, in patients with Alzheimer's Disease. We were honored to collaborate with Dr. Ana Pereira of Mount Sinai Icahn School of Medicine and others on this work.

Koenig et al. report that p-tau217 and glial fibrillary acidic protein (GFAP) levels in plasma are linked to hypometabolism on [18F]Fluorodeoxyglucose PET

04/02/2026

We're honored to receive this news from Alzheimer's & Dementia: We are delighted to share that your work, published in Alzheimer's & Dementia: Translational Research & Clinical Interventions, on behalf of Alzheimer's Association, is among our top 10 most-cited papers published by the journal in 2024*:

Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer's disease patients

07/12/2024

Our work regarding "Relationships between plasma biomarkers, Tau PET, FDG PET, and volumetric MRI in Mild to Moderate Alzheimer’s disease patients” has been published in Alzheimer's & Dementia: Translational Research & Clinical Interventions. This study, led by Dr. Jeffrey Cummings and Dr. Jefferson Kinney, with analysis by ADMdx, demonstrated correspondence between blood tests and imaging, the complimentary insight they provide to patient status, and the effects of covariates such as age.

Alzheimer's & Dementia: Translational Research & Clinical Interventions journal bridges drug discovery research and clinical studies for dementia & Alzheimer's.

10/27/2023

Honored to speak on the Biomarker panel at the Alzheimer's Drug Discovery Foundation Therapeutic Investigator Day. This symposium, along with the Clinical Trials in Alzheimer's Disease conference that followed, included an unprecedented set of encouraging research outcomes toward the effective treatment of Alzheimer's Disease.

09/18/2023

Recent research further supports the association between exercise (i.e. avoiding a sedentary lifestyle, such as sitting for 12 hours a day) and reduced risk of dementia. This study provided a possible biochemical mechanism behind the connection.

Sit Less, Move More to Induce Irisin and Stave Off Dementia Quick Links Article Comments References Further Reading Tools Add to my Library Follow Comments Share How would you like to share? Facebook Twitter LinkedIn Back to the Top 14 Sep 2023 Physical activity staves off dementia, but does that me...

05/03/2023

Our work was recently published in collaboration with Enigma/Cerveau (Lantheus) in the validation of a visual reading method for a new tau PET radiotracer, MK-6240. As part of this work, ADMdx read 1,842 tau PET scans and evaluated associations with amyloid and clinical status. Results were very well aligned with tau findings from neuropathology studies. The ability to "see" and measure tau in the brain in vivo is a powerful tool contributing to research, diagnosis, and ultimately treatment.

Background The positron emission tomography (PET) radiotracer [18F]MK-6240 exhibits high specificity for neurofibrillary tangles (NFTs) of tau protein in Alzheimer's disease (AD), high sensitivity t...

05/03/2023

Exciting news in Alzheimer's disease -- Lilly's anti-amyloid drug Donanemab has successfully met all of its Phase III pivotal clinical trial endpoints, slowing cognitive and functional decline in patients. This drug had been successful in its Phase II trial, but drugs often do not succeed in their larger Phase III trials. Donanemab removes an abnormal protein called amyloid in the brain, and in Phase II studies also showed a reduction of abnormal tau protein - - together, those two abnormal proteins (amyloid plaques and neurofibrillary tau tangles) constitute a diagnosis of Alzheimer's disease. This will be the third drug to be approved by the FDA (expected) as a disease-modifying therapeutic for Alzheimer's disease, and it is the first to actually meet all of its endpoints. There is still progress to be made in preventing and treating AD but this is a significant step and brings hope for patients with AD.

The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.

07/29/2022

Our work using machine learning and early frame amyloid PET to characterize neuronal function and predict cognitive decline was recently published in Alzheimer’s&DemTRCI:

Introduction Amyloid measurement provides important confirmation of pathology for Alzheimer's disease (AD) clinical trials. However, many amyloid positive (Am+) early-stage subjects do not worsen cl...

07/29/2022

Honored to be participating authors in the newly released book Alzheimer's Disease Drug Development - Research and Development Ecosystem, Edited by J Cummings, J Kinney, H Fillit:

Cambridge Core - Neurology and Clinical Neuroscience - Alzheimer's Disease Drug Development